AAUM (Average Assets Under Management) of ₹3,199.22 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 60.4% | 65.1% | ▲ +4.6% |
| Healthcare Services | 14.3% | 18.0% | ▲ +3.8% |
| Insurance | 1.2% | 1.1% | ▼ -0.1% |
| Healthcare Equipment & Supplies | 0.2% | 0.2% | ● 0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 65.1% | 66.4% | ▲ +1.4% |
| Healthcare Services | 18.0% | 20.4% | ▲ +2.3% |
| Insurance | 1.1% | 1.0% | ● -0.1% |
| Healthcare Equipment & Supplies | 0.2% | 0.1% | ● 0.0% |
Comparing Jul 2026 → Aug 2026
| # | Stock | Sector | Weight (Aug 2026) |
|---|---|---|---|
| 1 | Thyrocare Technologies Limited ₹81.07 Cr |
Healthcare Services | 2.11% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹159.26 Cr |
Pharmaceuticals & Biotechnology | 2.34% | 4.15% | +1.81% |
| 2 | Concord Biotech Limited ₹106.41 Cr |
Pharmaceuticals & Biotechnology | 1.95% | 2.77% | +0.82% |
| 3 | Manipal Health Enterprises Ltd ₹141.84 Cr |
Healthcare Services | 3.02% | 3.70% | +0.68% |
| 4 | Apollo Hospitals Enterprise Limited ₹248.03 Cr |
Healthcare Services | 5.81% | 6.47% | +0.66% |
| 5 | IPCA Laboratories Limited ₹335.02 Cr |
Pharmaceuticals & Biotechnology | 8.17% | 8.74% | +0.57% |
| 6 | Pfizer Limited ₹123.49 Cr |
Pharmaceuticals & Biotechnology | 2.73% | 3.22% | +0.49% |
| 7 | Sai Life Sciences Limited ₹285.72 Cr |
Pharmaceuticals & Biotechnology | 7.10% | 7.45% | +0.35% |
| 8 | Indoco Remedies Ltd ₹78.98 Cr |
Pharmaceuticals & Biotechnology | 1.96% | 2.06% | +0.10% |
| 9 | Cohance Lifesciences Limited ₹146.04 Cr |
Pharmaceuticals & Biotechnology | 3.75% | 3.81% | +0.06% |
| 10 | Kovai Medical Center and Hospital Limited ₹107.41 Cr |
Healthcare Services | 2.74% | 2.80% | +0.06% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Vijaya Diagnostic Centre Limited ₹93.49 Cr |
Healthcare Services | 3.47% | 2.44% | -1.03% |
| 2 | Cipla Limited ₹282.03 Cr |
Pharmaceuticals & Biotechnology | 8.13% | 7.35% | -0.78% |
| 3 | Alkem Laboratories Limited ₹156.61 Cr |
Pharmaceuticals & Biotechnology | 4.66% | 4.08% | -0.58% |
| 4 | Procter & Gamble Health Limited ₹91.88 Cr |
Pharmaceuticals & Biotechnology | 2.90% | 2.40% | -0.50% |
| 5 | Sun Pharmaceutical Industries Limited ₹304.78 Cr |
Pharmaceuticals & Biotechnology | 8.42% | 7.95% | -0.47% |
| 6 | Gland Pharma Limited ₹229.50 Cr |
Pharmaceuticals & Biotechnology | 6.35% | 5.98% | -0.37% |
| 7 | ICICI Lombard General Insurance Company Limited ₹37.83 Cr |
Insurance | 1.08% | 0.99% | -0.09% |
| 8 | Aarti Drugs Ltd ₹35.08 Cr |
Pharmaceuticals & Biotechnology | 0.99% | 0.91% | -0.08% |
| 9 | Eris Lifesciences Limited ₹29.30 Cr |
Pharmaceuticals & Biotechnology | 0.84% | 0.76% | -0.08% |
| 10 | Jupiter Life Line Hospitals Limited ₹15.27 Cr |
Healthcare Services | 0.47% | 0.40% | -0.07% |
26 stocks — Aug 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹335.02 Cr |
Pharmaceuticals & Biotechnology |
8.74%
|
|
| 2 |
₹304.78 Cr |
Pharmaceuticals & Biotechnology |
7.95%
|
|
| 3 |
₹285.72 Cr |
Pharmaceuticals & Biotechnology |
7.45%
|
|
| 4 |
₹282.03 Cr |
Pharmaceuticals & Biotechnology |
7.35%
|
|
| 5 |
₹248.03 Cr |
Healthcare Services |
6.47%
|
|
| 6 |
₹229.50 Cr |
Pharmaceuticals & Biotechnology |
5.98%
|
|
| 7 |
₹159.26 Cr |
Pharmaceuticals & Biotechnology |
4.15%
|
|
| 8 |
₹156.61 Cr |
Pharmaceuticals & Biotechnology |
4.08%
|
|
| 9 |
₹146.04 Cr |
Pharmaceuticals & Biotechnology |
3.81%
|
|
| 10 |
₹141.84 Cr |
Healthcare Services |
3.70%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.